AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18694333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose pyronaridine-artesunate combination (6:2, 9:3, 12:4 mg/kg tablet coformulations and 9:3 mg/kg granule coformulation) administered once daily for 3 days
Number of subjects: 60
Study 18694333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose pyronaridine-artesunate combination
Number of subjects: 60
Study 18694338 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of 90 microg of inactivated subvirion A/Vietnam/1203/2004 vaccine
Number of subjects: 37
Study 18694338 — intervention group
Group type: COMPARATOR
Intervention: Two 90-microg doses in H5-naive subjects
Number of subjects: 37
Study 18697817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (apnea-hypopnea index >or=5)
Number of subjects: 392
Study 18697817 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index 5 to 15
Number of subjects: 392
Study 18697817 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index >or=15
Number of subjects: 392
Study 18697817 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting or percutaneous coronary intervention
Number of subjects: 392
Study 18697817 — intervention group
Group type: COMPARATOR
Intervention: No sleep apnea
Number of subjects: 392
Study 18698002 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic donor peripheral blood cells infusion after fludarabine and 200 cGy total body irradiation, with posttransplantation cyclosporine and mycophenolate mofetil.
Number of subjects: 0
Study 18698002 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted administration of highly active antiretroviral therapy (HAART).
Number of subjects: 0
Study 18698342 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 21
Study 18703791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-alpha-trypsin inhibitor (IaI)
Number of subjects: 0
Study 18703791 — intervention group
Group type: COMPARATOR
Intervention: Inter-alpha-trypsin inhibitor (IaI) deficiency
Number of subjects: 0
Study 18703791 — intervention group
Group type: COMPARATOR
Intervention: Serum IaI and HA levels in patients with IPF
Number of subjects: 0
Study 18703791 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IaI and HA levels
Number of subjects: 0
Study 18707849 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (1g within 1h of infusion for three consecutive days)
Number of subjects: 200
Study 18707849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18707849 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 200
Study 18708295 — intervention group
Group type: EXPERIMENTAL
Intervention: MRL (MR lymphoangiography)
Number of subjects: 375
Study 18708295 — intervention group
Group type: COMPARATOR
Intervention: MDCT (multidetector CT)
Number of subjects: 375
Study 18711462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV) implantation in UG patients
Number of subjects: 68
Study 18711462 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma valve (AGV) implantation in OAG patients
Number of subjects: 68
Study 18713945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg for 2 weeks, then 400 mg for 50 weeks) and rituximab (375 mg/m2 per week)
Number of subjects: 25
Study 18713945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide and rituximab
Number of subjects: 25
Study 18713945 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 25
Study 18719057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic mountain sickness patients (CMS)
Number of subjects: 55
Study 18719057 — intervention group
Group type: COMPARATOR
Intervention: Healthy men living at high altitude (HA)
Number of subjects: 55
Study 18719057 — intervention group
Group type: COMPARATOR
Intervention: Healthy men living at sea level (SL)
Number of subjects: 55
Study 18722008 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC124 at 16 mg/kg per day for 14 days (first cycle)
Number of subjects: 44
Study 18722008 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC124 at 40 mg/kg per day for 14 days (second cycle)
Number of subjects: 44
Study 18723429 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated donor umbilical cord blood transplantation
Number of subjects: 191
Study 18725917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte depletion
Number of subjects: 0
Study 18726086 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 0
Study 18726086 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18726828 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin replacement treatment with recombinant methionyl human leptin for 24 months
Number of subjects: 1
Study 18728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient 1-yr intervention program based on exercise, behavior, and nutrition therapy
Number of subjects: 36
Study 18728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children with NAFLD
Number of subjects: 36
Study 18728159 — intervention group
Group type: COMPARATOR
Intervention: Obese children without NAFLD
Number of subjects: 36
Study 18728159 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes of fetuin-A
Number of subjects: 36
Study 18729192 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-478 (20 mumol/L)
Number of subjects: 2
Study 18729192 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-478 (50 mumol/L)
Number of subjects: 2
Study 18729192 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-478
Number of subjects: 2
Study 18729283 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 0
Study 18753661 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm needle for intramuscular injections
Number of subjects: 0
Study 18757456 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in individuals with COPD (n=1888)
Number of subjects: 2652
Study 18757456 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in current smokers with COPD
Number of subjects: 2652
Study 18757456 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in former smokers with COPD
Number of subjects: 2652
Study 18757456 — intervention group
Group type: COMPARATOR
Intervention: Serum CC-16 levels in individuals without airflow obstruction (n=296)
Number of subjects: 2652
Study 18757456 — intervention group
Group type: COMPARATOR
Intervention: Serum CC-16 levels in non-smokers (n=201)
Number of subjects: 2652
Study 18757456 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum CC-16 levels with age and gender in COPD subjects
Number of subjects: 2652
Study 18757456 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in individuals with GOLD stage II and III COPD
Number of subjects: 2652
Study 18757456 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in former smokers with reversible airflow obstruction
Number of subjects: 2652
Study 18758745 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction intervention (diet-induced weight loss) for 33 weeks
Number of subjects: 34
Study 18758745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight-reduction intervention)
Number of subjects: 34
Study 18761748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 14
Study 18761748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment in aggregate-containing tissues
Number of subjects: 14
Study 18761748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment in aggregate-containing synovia
Number of subjects: 14
Study 18761748 — intervention group
Group type: COMPARATOR
Intervention: RA synovia compared with serum
Number of subjects: 14
Study 18762599 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 12 to 15 years
Number of subjects: 10745
Study 18762599 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age younger than 25 years
Number of subjects: 10745
Study 18762599 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger mothers (under 25)
Number of subjects: 10745
Study 18765432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin
Number of subjects: 1873
Study 18765432 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1873
Study 18765432 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1873
Study 18769450 — intervention group
Group type: EXPERIMENTAL
Intervention: BACH2 siRNA transfection in UCB CD4(+) T cells
Number of subjects: 0
Study 18769450 — intervention group
Group type: COMPARATOR
Intervention: UCB CD4(+) T cells
Number of subjects: 0
Study 18769731 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r-metHuLeptin) at physiologic replacement doses of 0.03 mg/kg/day
Number of subjects: 1
Study 18769731 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r-metHuLeptin)
Number of subjects: 1
Study 18771667 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day Silibinin (IV) for 7 days
Number of subjects: 36
Study 18771667 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36
Study 18771667 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36
Study 18771667 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36
Study 18771667 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36
Study 18771667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Silibinin/PegIFN/RBV
Number of subjects: 36
Study 18774548 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D OCT-1000 (Fourier-domain OCT)
Number of subjects: 36
Study 18774548 — intervention group
Group type: COMPARATOR
Intervention: Stratus OCT (Time-domain OCT)
Number of subjects: 36
Study 18776118 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II blockers added to ACE inhibitors
Number of subjects: 0
Study 18776118 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RAAS blockade (ACE inhibitors + Angiotensin II blockers)
Number of subjects: 0
Study 18776118 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors alone
Number of subjects: 0
Study 18776138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (5 pmol . kg(-1) . min(-1))
Number of subjects: 14
Study 18778241 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART including nevirapine (96%) or efavirenz (4%)
Number of subjects: 596
Study 18778916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 54
Study 18779469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium, 5000 IU once daily
Number of subjects: 138
Study 18780832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 237
Study 18780832 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone incubation
Number of subjects: 237
Study 18781879 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg of L-AmB alone (group A)
Number of subjects: 226
Study 18781879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B)
Number of subjects: 226
Study 18781879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of L-AmB followed by miltefosine for 14 days (group C)
Number of subjects: 226
Study 18781879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D)
Number of subjects: 226
Study 18781879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E)
Number of subjects: 226
Study 18784101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab (cisplatin or carboplatin plus fluorouracil with cetuximab at 400 mg/m² initially, then 250 mg/m² weekly)
Number of subjects: 442
Study 18784101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 442
Study 18784101 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin or carboplatin plus fluorouracil)
Number of subjects: 442
Study 18784101 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 442
Study 18784623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab intravitreally in the worst eye
Number of subjects: 23
Study 18786266 — intervention group
Group type: EXPERIMENTAL
Intervention: DrotAA (24 microg/kg per hour) infused for 96 hours
Number of subjects: 0
Study 18786266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18786301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS Therapy)
Number of subjects: 0
Study 18791359 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe burn injury
Number of subjects: 242
Study 18794207 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 119
Study 18794207 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-6 mg/day)
Number of subjects: 119
Study 18794207 — intervention group
Group type: COMPARATOR
Intervention: Molindone (10-140 mg/day, plus 1 mg/day of benztropine)
Number of subjects: 119
Study 18794456 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estradiol 0.01%, 0.1%, 1%, or 2.5%
Number of subjects: 70
Study 18794456 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 70
Study 18794722 — intervention group
Group type: EXPERIMENTAL
Intervention: 22GA genotype (n=5)
Number of subjects: 96
Study 18794722 — intervention group
Group type: COMPARATOR
Intervention: GG genotype (n=35)
Number of subjects: 96
Study 18799002 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity intervention program 'Obeldicks'
Number of subjects: 207
Study 18799002 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk A-allele of rs9939609
Number of subjects: 207
Study 18799354 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle changes
Number of subjects: 30
Study 18799557 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 2600
Study 18799726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + dexamethasone
Number of subjects: 704
Study 18799726 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 704
Study 18803826 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation lens (VARILUX PANAMIC ORMA CRIZAL)
Number of subjects: 127
Study 18803826 — intervention group
Group type: COMPARATOR
Intervention: Older-generation lens (VARILUX CONFORT ORMA CRIZAL)
Number of subjects: 127
Study 18805103 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fasting (abstinence from food and drink)
Number of subjects: 448
Study 18805103 — intervention group
Group type: COMPARATOR
Intervention: LDS members
Number of subjects: 448
Study 18805103 — intervention group
Group type: COMPARATOR
Intervention: Non-LDS members
Number of subjects: 448
Study 18805967 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 18805967 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 0
Study 18806079 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum TSH levels at 4 weeks postpartum
Number of subjects: 51
Study 18806079 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive postnatal thyroid antibody tests
Number of subjects: 51
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mansonella perstans infection in Mukono community
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mansonella perstans infection in Luwero community
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 1-4 years in Mukono
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 1-4 years in Luwero
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 15-19 years in Mukono
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 15-19 years in Luwero
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean mf intensity in Mukono
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean mf intensity in Luwero
Number of subjects: 1566
Study 18809192 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical parameters
Number of subjects: 1566
Study 18812445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg qd for 4 weeks followed by 5 mg/d for 8 weeks
Number of subjects: 36
Study 18812445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan treatment
Number of subjects: 36
Study 18813343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 74
Study 18816386 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg IT morphine
Number of subjects: 60
Study 18816386 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg IT morphine
Number of subjects: 60
Study 18816386 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg IT morphine
Number of subjects: 60
Study 18816386 — intervention group
Group type: COMPARATOR
Intervention: Control (100 μg IT morphine)
Number of subjects: 60
Study 18816386 — intervention group
Group type: COMPARATOR
Intervention: Control (200 μg IT morphine)
Number of subjects: 60
Study 18816386 — intervention group
Group type: COMPARATOR
Intervention: Control (300 μg IT morphine)
Number of subjects: 60
Study 18816600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory evoked potentials (SEPs) assessment in polio survivors
Number of subjects: 22
Study 18816600 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) evaluation
Number of subjects: 22
Study 18823688 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD) 6 times/week with the NxStage System One device
Number of subjects: 500
Study 18823688 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly in-center hemodialysis (HD)
Number of subjects: 500
Study 18823688 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD)
Number of subjects: 500
Study 18824593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, single-agent lenalidomide
Number of subjects: 2
Study 18824593 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 2
Study 18824594 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (ASCT)
Number of subjects: 7
Study 18825363 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant (IR) individuals
Number of subjects: 33
Study 18825363 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive (IS) individuals
Number of subjects: 33
Study 18829231 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated ABI measurement using corrected ankle pressure formula
Number of subjects: 100
Study 18829231 — intervention group
Group type: COMPARATOR
Intervention: Supine ABI measurement
Number of subjects: 100
Study 18832245 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc plus optimized background therapy (OBT)
Number of subjects: 0
Study 18832245 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus optimized background therapy (OBT)
Number of subjects: 0
Study 18832245 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc plus OBT
Number of subjects: 0
Study 18834580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide eye drops
Number of subjects: 7
Study 18838471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk cytogenetics and/or at least two of the following: age >= 75 years, performance status >= 2, white cell count >= 50 x 10(9)/L
Number of subjects: 416
Study 18838471 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive chemotherapy
Number of subjects: 416
Study 18838477 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg daily
Number of subjects: 92
Study 18842912 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tracheobronchoplasty
Number of subjects: 77
Study 18845370 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(cysC) of 60 to 75 mL/min/1.73 m(2)
Number of subjects: 4971
Study 18845370 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(cysC) less than 60 mL/min/1.73 m(2)
Number of subjects: 4971
Study 18846045 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese cohort
Number of subjects: 70
Study 18849604 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced cardiac magnetic resonance (ceCMR) scanning before discharge
Number of subjects: 100
Study 18849604 — intervention group
Group type: COMPARATOR
Intervention: Standard transthoracic echocardiography (TTE)
Number of subjects: 100
Study 18851740 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative physiological index approach (SPINA)
Number of subjects: 0
Study 18851740 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of variables quantifying distinct components of NTIS
Number of subjects: 0
Study 18851740 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative follow-up of NTIS
Number of subjects: 0
Study 18851740 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological impact assessment of NTIS
Number of subjects: 0
Study 18851761 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T, 3TC and NVP
Number of subjects: 140
Study 18851761 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T, 3TC and NVP with rifampicin
Number of subjects: 140
Study 18851761 — intervention group
Group type: COMPARATOR
Intervention: d4T, 3TC and NVP without rifampicin
Number of subjects: 140
Study 18851761 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 140
Study 18851871 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm utilizing HE4 and CA125
Number of subjects: 531
Study 18852348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (3 to 9 g per night in split doses over 6 weeks)
Number of subjects: 38
Study 18854394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg twice daily for 2 weeks, followed by 1 week off therapy)
Number of subjects: 19